Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE SODIUM versus XELODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE SODIUM versus XELODA.
METHOTREXATE SODIUM vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with purine and pyrimidine synthesis, leading to inhibition of DNA replication and cell proliferation. It also has immunomodulatory effects via adenosine release.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
10-25 mg orally, intramuscularly, intravenously, or subcutaneously once weekly for rheumatoid arthritis; 7.5-15 mg orally once weekly for psoriasis. For oncology regimens, dosing varies (e.g., 50 mg/m² IV once weekly, or 1-5 g/m² IV with leucovorin rescue).
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Terminal elimination half-life is 3-10 hours for low doses (≤50 mg/m²) and 8-15 hours for high doses (>50 mg/m²); in chronic therapy for rheumatoid arthritis, the half-life is approximately 5-8 hours.
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Renal excretion accounts for 80-90% of elimination via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for 10-20%.
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category D/X
Category C
Antimetabolite
Antimetabolite